CJC-1295 DAC and ipamorelin dosage ranges, timing, and DAC vs no-DAC differences, plus safety notes for researchers comparing peptide protocols.
The typical CJC-1295 DAC and ipamorelin dosage in research protocols is 1–2 mg of CJC-1295 DAC once or twice per week, paired with 100–300 mcg of ipamorelin one to three times per day. The two compounds run on completely different schedules because CJC-1295 DAC has a half-life of roughly six to eight days, while ipamorelin clears the body within a few hours. Neither peptide is FDA-approved for human use, so the numbers below describe laboratory research practice, not a clinical prescription.
What CJC-1295 DAC and Ipamorelin Do
CJC-1295 is a growth hormone-releasing hormone (GHRH) analog. Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin. Researchers pair them because they hit two different receptors, and the combination is studied for its effect on pulsatile growth hormone release.
Three differences matter most when comparing protocols:
- CJC-1295 DAC binds to albumin, which extends its activity for days after a single injection.
- CJC-1295 without DAC (also called MOD GRF 1-29) has a half-life measured in minutes and is dosed much like ipamorelin.
- Ipamorelin is often described as more selective, with less impact on cortisol and prolactin in early animal data.
CJC-1295 DAC and Ipamorelin Dosage Chart
The table below summarizes the ranges most often cited in research discussions. Every entry is a reference point for study design, not a recommendation for personal use.
| Compound | Common research dose | Frequency | Notes |
|---|---|---|---|
| CJC-1295 DAC | 1–2 mg | 1–2x per week | Long half-life of about 6–8 days |
| CJC-1295 no DAC | 100–300 mcg | 1–3x per day | Short half-life of about 30 minutes |
| Ipamorelin | 100–300 mcg | 1–3x per day | Short half-life; usually stacked |
| CJC-1295 DAC + ipamorelin | 1–2 mg weekly + 100–300 mcg daily | Split schedules | Half-lives do not match |
| 10 mg blend (5 mg no DAC + 5 mg ipamorelin) | 100–300 mcg total | 1–3x per day | Single vial, matched half-lives |
How the DAC Variant Changes the Dosing Math
CJC-1295 with DAC is dosed by the week; CJC-1295 without DAC is dosed by the hour. That single difference explains most of the confusion researchers run into when comparing protocols.
A standard cjc-1295 dac with ipamorelin dosage plan uses 1 mg twice weekly or 2 mg once weekly alongside daily ipamorelin. Because the DAC peptide stays active for days, adding more frequent injections mainly increases cumulative exposure rather than producing a sharper pulse.
The shorter-acting version works differently. A typical cjc-1295 no dac dosage is 100–300 mcg per injection, usually stacked one-to-one with ipamorelin so both peptides peak and clear on the same timeline.
Pre-mixed vials simplify that arithmetic. A cjc-1295 no dac ipamorelin 10mg blend dosage is normally calculated as one total dose of 100–300 mcg, since the vial already contains equal parts of both peptides.
Injection Timing and Cycle Length
Timing matters far more with short-acting peptides than with DAC. Most protocols place ipamorelin injections before meals or before sleep, when natural growth hormone release is highest.
Practical timing notes
- Inject on an empty stomach when possible; food, especially carbohydrates, can blunt the growth hormone response.
- Space multiple daily doses at least three to four hours apart.
- Keep DAC injections on the same days each week to hold exposure steady.
Cycle length varies widely in the literature and in user reports. Many protocols run 8–12 weeks followed by a break, but no controlled human trial establishes an optimal schedule for either peptide.
Reported Results and Realistic Expectations
User reports are not evidence, but they shape what people search for. When people compare cjc-1295 ipamorelin results before and after logs, the changes most often described are better sleep quality, faster recovery between training sessions, and gradual shifts in body composition over several months.
Expectations should stay modest. Growth hormone and IGF-1 increases seen in small studies are real but generally smaller than what supraphysiological HGH dosing produces, and individual responses vary widely.
Forums carry a lot of anecdotal data. Threads such as cjc 1295 no dac ipamorelin reddit discussions often blend personal experience with speculation, so treat them as leads rather than proof.
Safety, Sourcing, and Legal Status
CJC-1295 and ipamorelin are not approved by the FDA for human use in the United States and are sold as research chemicals only. Purity, sterility, and actual peptide content in those vials are not verified by any regulator.
Reported side effects in research and anecdotal settings include injection-site irritation, headaches, water retention, and fatigue. Because both compounds influence growth hormone and IGF-1 signaling, anyone with a history of cancer, diabetes, or pituitary disorders should be especially cautious.
Anyone considering these peptides should speak with a licensed healthcare professional first. Baseline bloodwork and medical supervision are not optional extras when a compound alters growth signaling.
RELATED PEPTIDE TOPICresearch peptide IpamorelinFrequently Asked Questions
What is a typical CJC-1295 DAC and ipamorelin dosage?
Research protocols most often cite 1–2 mg of CJC-1295 DAC per week, split into one or two injections, combined with 100–300 mcg of ipamorelin once to three times daily. The mismatch in frequency exists because CJC-1295 DAC stays active for days while ipamorelin clears in hours. These figures come from research discussion, not from approved clinical dosing.
How does CJC-1295 without DAC change the schedule?
CJC-1295 without DAC has a half-life of roughly 30 minutes, so it is dosed at 100–300 mcg one to three times per day instead of weekly. That schedule matches ipamorelin closely, which is why the two are frequently combined in a single 10 mg vial. Researchers who switch from the DAC version usually reduce total weekly peptide volume.
Is CJC-1295 DAC with ipamorelin FDA-approved?
No. CJC-1295 and ipamorelin are not FDA-approved for human use in the United States and are legally sold only as research chemicals. That means no regulator verifies their purity, sterility, or label accuracy. Anyone considering them should consult a licensed healthcare professional and review the legal status in their state.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.